Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal [MarketWatch]
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: MarketWatch
Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal Shares of Kura Oncology Inc. KURA, +4.32% soared 27% toward a record high in premarket trading Friday, after the biopharmaceutical company announced a phase 2 trial of its lymphoma treatment achieved its primary efficacy endpoint. The stock was on track to open above its March 2, 2018 record close of $23.40. The company said the results of the trial demonstrated "ongoing anti-tumor activity and a manageable safety profile" in advanced patients with angioimmunoblastic T-cell lymphoma (AITL), as well as non-AITL relapsed or refractory peripheral T-cell lymphoma (PTCL). "We believe these data support the potential to register tipifarnib in both the AITL and PTCL-NOS patient populations, and we look forward to seeking regulatory feedback on next steps for this program," said Chief Executive Troy Wilson. The stock has run up 32% year to date through Thursday, while the iShares Nasdaq Biotechno
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- Kura Oncology, Inc. (NASDAQ: KURA) had its price target lowered by analysts at Bank of America Co. from $36.00 to $29.00. They now have a "buy" rating on the stock.MarketBeat
- Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at TD Cowen.MarketBeat
- Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% [Yahoo! Finance]Yahoo! Finance
- Kura Oncology, Inc. (NASDAQ: KURA) had its price target lowered by analysts at Jefferies Financial Group Inc. from $32.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
- Kura Oncology, Inc. (NASDAQ: KURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
KURA
Earnings
- 11/7/24 - Beat
KURA
Sec Filings
- 11/20/24 - Form 8-K
- 11/19/24 - Form 4
- 11/18/24 - Form 144
- KURA's page on the SEC website